Tag: FDA

Top News Stories November 28 2017

28/11/2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list. Apple Inc. (AAPL) Apple was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 42,832,149 shares, an increase of 27.9% from the October 31st total of 33,490,296 shares. Based on Read More ยป

Adamis Pharmaceuticals stock chart looks like a falling knife.

Adamis Pharmaceuticals Could Explode Over 130 Percent

19/11/2017

Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.

Intercept Pharmaceuticals stock chart shows rising large players volume.

Intercept Pharmaceuticals Rising Large Players Volume

5/11/2017

Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.

Bluebird Bio Stock Strong Uptrend On Buy Ratings

5/11/2017

While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.

Abbott Laboratories stock shows a pullback to uptrend line support.

Abbott Laboratories Gets FDA Clearance for its Alinity

1/11/2017

We have been stalking Abbott Laboratories for an entry. With FDA clearance of its Alinity mobile blood test unit and recent pullback, now may be the time for an entry.

Exelixis stock looks like a good swing long setup.

Exelixis Candle Over Candle Swing Trade Setup

30/10/2017

SUBSCRIBE OR SIGN IN

Sorrento Therapeutics stock has done a 61.8 percent Fibonacci retracement.

Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement

22/10/2017

SUBSCRIBE OR SIGN IN

Verastem Inc stock chart is oversold.

Verastem Inc Price Target Raised By Cantor Fitzgerald

22/10/2017

SUBSCRIBE OR SIGN IN

TransEnterix stock has done a 50 percent retracement after getting FDA approval.

Transenterix Stock 50 Percent Retracement After FDA Approval

22/10/2017

SUBSCRIBE OR SIGN IN

Exelixis Gets FDA Priority Review for Cabomteyx

18/10/2017

SUBSCRIBE OR SIGN IN

Mannkind Corporation Stock 38.2 Percent Retracement On Analyst Buy

15/10/2017

SUBSCRIBE OR SIGN IN

Flexion Therapeutics Offering To Raise $122.4 Million

12/10/2017

SUBSCRIBE OR SIGN IN